AR1001 (AriBio)
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ar1001-aribio</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>AR1001</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Synaptic function & vascular health</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Oral small molecule</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Direct CNS penetration</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>No ARIA concerns</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">NCT Number</td>
<td>NCT05531526</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Enrollment</td>
<td>1,535 participants</td>
</tr>
<tr>
<td class="label">Treatment Duration</td>
<td>52 weeks</td>
</tr>
<tr>
<td class="label">Primary Endpoint</td>
<td>CDR-SB (Clinical Dementia Rating - Sum of Boxes)</td>
</tr>
<tr>
<td class="label">Sponsor</td>
<td>AriBio Co., Ltd.</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td class="label">Completion</td>
<td>Expected 2027</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target/Mechanism</td>
</tr>
<tr>
<td class="label">AR1001</td>
<td>PDE5 inhibitor</td>
</tr>
<tr>
<td class="label">AR1002</td>
<td>Tau aggregation inhibitor</td>
</tr>
<tr>
<td class="label">AR1003</td>
<td>Anti-amyloid antibody</td>
</tr>
</table>
Overview
AR1001 is a novel [phosphodiesterase 5 (PDE5) inhibitor](/mechanisms/phosphodiesterase-inhibition) developed by [AriBio Co., Ltd.](/companies/ari-bio), a South Korean biotechnology company, for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease)[@aribio]. Unlike amyloid-targeting monoclonal antibodies, AR1001 represents a small molecule approach that targets synaptic function and vascular health through enhancement of cyclic guanosine monophosphate (cGMP) signaling.
AR1001 is currently in [Phase 3 clinical development](/clinical-trials/nct05531526) (Polaris-AD trial, NCT05531526) with over 1,500 participants enrolled[@phase3].
Mechanism of Action
PDE5 Inhibition and cGMP Signaling
AR1001 works by inhibiting the [phosphodiesterase 5](/proteins/pde5) enzyme, which degrades cGMP in neurons and vascular smooth muscle cells. This inhibition leads to:
- Increased intracellular cGMP levels: Enhanced cyclic GMP signaling promotes neuronal survival and synaptic plasticity
- Improved cerebral blood flow: Vasodilation through cGMP-mediated smooth muscle relaxation
- Enhanced synaptic plasticity: cGMP is essential for long-term potentiation (LTP), the cellular basis of memory formation
- Neuroprotective effects: Anti-apoptotic and anti-inflammatory properties of cGMP signaling
Differentiation from Amyloid-Targeted Therapies
AR1001 offers a distinctly different mechanism compared to approved [anti-amyloid antibodies](/therapeutics/anti-amyloid-therapeutics):
Relevance to Alzheimer's Disease Pathophysiology
The PDE5 pathway is relevant to AD through several mechanisms:
Synaptic plasticity: cGMP signaling is essential for LTP and memory formation
Neuroprotection: cGMP has anti-apoptotic and anti-inflammatory effects
Vascular function: PDE5 inhibition improves cerebral blood flow
Amyloid interaction: cGMP signaling can modulate amyloid-beta production and toxicityPreclinical studies have demonstrated that PDE5 inhibition improves memory in animal models of AD, supporting clinical development[@pde5mech].
Clinical Development
Phase 2 Trial (NCT05463780)
The Phase 2 trial established the safety and preliminary efficacy of AR1001 in patients with mild-to-moderate Alzheimer's disease[@phase2]:
- Randomized, double-blind, placebo-controlled design
- Primary endpoints: Cognitive function (ADAS-Cog13), functional capacity (ADCS-ADL)
- Demonstrated favorable safety and tolerability
- Good brain penetration achieved
- Results informed Phase 3 dose selection
Phase 3 Trial: Polaris-AD (NCT05531526)
The Phase 3 Polaris-AD trial is a randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of AR1001 over 52 weeks in participants with early Alzheimer's disease[@phase3].
Trial Design
Patient Population
The trial enrolls participants with early Alzheimer's disease, including:
- Mild cognitive impairment (MCI) due to AD
- Mild dementia due to AD
- Confirmed amyloid pathology (PET or CSF biomarkers)
Key Inclusion Criteria
- Clinical diagnosis of MCI or mild AD dementia
- Confirmed amyloid pathology via PET or CSF
- MMSE score of 20-30
- Stable cholinesterase inhibitor or memantine use (if applicable)
- Caregiver availability for assessment support
Clinical Endpoints
Primary Endpoint: CDR-SB
The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) is the gold-standard primary endpoint for AD clinical trials[@cdrsb]. This instrument assesses:
- Memory
- Orientation
- Judgment and problem-solving
- Community affairs
- Home and hobbies
- Personal care
Each domain is scored from 0 (no impairment) to 3 (severe impairment), with total scores ranging from 0 to 18.
Secondary Endpoints
The trial includes multiple secondary endpoints:
- Cognitive batteries (ADAS-Cog, MMSE)
- Functional assessments (ADCS-ADL)
- Behavioral measures (NPI)
- Biomarker endpoints (amyloid PET, tau PET, CSF biomarkers)
- Quality of life measures
Safety Profile
PDE5 Inhibitor Class Safety
The PDE5 inhibitor class (including sildenafil, tadalafil, vardenafil) has a well-characterized safety profile from cardiovascular and urology indications:
Common side effects:
- Headache
- Flushing
- Dyspepsia
- Visual changes
- Nasal congestion
Important precautions:
- Contraindicated with nitrates (risk of hypotension)
- Caution in severe cardiovascular disease
- Rare non-arteritic anterior ischemic optic neuropathy (NAION)
AR1001-Specific Considerations
As a CNS-penetrant PDE5 inhibitor optimized for Alzheimer's disease:
- Enhanced CNS effects (both therapeutic and potential side effects)
- Different drug-drug interaction profile compared to peripheral PDE5 inhibitors
- Specific monitoring for cognitive effects
- 52-week exposure allows assessment of sustained tolerability
Therapeutic Potential
Unmet Need Addressed
AR1001 addresses significant unmet needs in Alzheimer's disease treatment:
Oral administration: Easier accessibility compared to IV infusions for amyloid antibodies
Different mechanism: Provides alternative for patients who cannot receive amyloid antibodies
Synaptic targeting: Addresses downstream synaptic failure rather than upstream amyloid
Combination potential: May be combined with other therapeutic approachesCompetitive Position
If successful, AR1001 would be the first PDE5 inhibitor approved for Alzheimer's disease, offering:
- Oral, small molecule convenience
- Different mechanism for non-responders to amyloid approaches
- Potential for combination therapy with approved AD treatments
- Manageable safety profile without ARIA concerns
Pipeline and Future Directions
AriBio Pipeline
Combination Therapy Potential
PDE5 inhibition may synergize with other approaches:
- Combined with [amyloid antibodies](/therapeutics/lecanemab)
- With [tau-targeting agents](/therapeutics/anti-tau-therapeutics)
- With neuroprotective compounds
Cross-References
Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Phosphodiesterase Inhibitors for Neurodegeneration](/therapeutics/phosphodiesterase-inhibitors-neurodegeneration)
- [PDE5 Protein](/proteins/pde5)
- [AriBio Company](/companies/ari-bio)
- [Polaris-AD Phase 3 Trial (NCT05531526)](/clinical-trials/nct05531526)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Synaptic Failure in AD](/mechanisms/synaptic-failure-alzheimers)
- [Lecanemab (Leqembi](/therapeutics/lecanemab) — Anti-amyloid antibody
- [Donanemab (Kisunla](/therapeutics/donanemab) — Anti-amyloid antibody
- [Small Molecule Therapeutics for AD](/therapeutics/small-molecule-drugs)
- [Neuroprotective Agents](/therapeutics/neuroprotection)
References
[AriBio Corporate Website](https://www.aribio.co.kr)
[AR1001 Phase 2 Trial Design - ClinicalTrials.gov NCT05463780](https://clinicaltrials.gov/ct2/show/NCT05463780)
[AR1001 Phase 3 Trial (Polaris-AD) - ClinicalTrials.gov NCT05531526](https://clinicaltrials.gov/study/NCT05531526)
[Baleztena et al., PDE5 Inhibitors and Neuroprotection in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[AR1001: A novel phosphodiesterase 5 inhibitor for Alzheimer's disease therapy (2024)](https://doi.org/10.1016/j.jalz.2024.02.018)
[Morris et al., Clinical Dementia Rating Sum of Boxes in Alzheimer's disease trials (2023)](https://doi.org/10.1016/j.trci.2023.01.005)